Glenmark Pharmaceuticals witnessed a rise in share price on Wednesday after the company has been granted final approval by the United States Food & Drug Administration (USFDA) for Atomoxetine Capsules USP, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, the generic version of Strattera Capsules, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, of Eli Lilly and company.

Shares of Glenmark Pharmaceutical are trading at Rs 637.50, up Rs 12.95, or 2.07% at the Bombay Stock Exchange (BSE) on Wednesday at 9:55 a.m.

The scrip has touched an intra-day high of Rs 639.10 and low of Rs 630. The total volume of shares traded at the BSE is 41,373.

Total volume of shares traded on the bourses today was lower by 85.97% to 442,436 compared with 22-day average volume of 3,153,748.